Fort Lauderdale, FL – According to filings with the U.S. Securities and Exchange Commission, ImmunSYS is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Eamonn Hobbs played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ImmunSYS

ImmunSYS is at the forefront of an entirely new approach to treating cancer. Our platform therapy has been shown to be effective in some metastatic cancers and may have wide applications as a cancer treatment for several solid tumor cancers. The company’s revolutionary therapy, YourVaccx utilizes a novel combination of controlled cell lysis and a triple-component immunotherapeutic drug. This new immunotherapy-focused therapy is designed to empower the immune system to recognize and selectively attack cancer cells throughout the body. The company is initially developing the new cancer therapy for the treatment of metastatic prostate cancer, with a pipeline of additional development programs for other solid tumor cancers.

To learn more about ImmunSYS, visit http://immunsys.com/

Contact:
Eamonn Hobbs, Chief Executive Officer
646-734-6972
ehobbs@immunsys.com
https://www.linkedin.com/in/eamonn-hobbs-a363b36/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved